About
WHO WE ARE
Founded in 2018, we are an international leader in the development of in-vivo biomarkers to guide targeted therapies in oncology.
OUR MISSION
We develop in-vivo biomarkers transforming oncology, guiding treatment selection and monitoring, improving patients’ pathway and quality of life. Within a Positron Emission Tomography exam (PET Scan), biomarkers help oncologists and nuclear medicine physicians personalize the treatment, based on whole body imaging providing the localization and characteristics of tumors.
MEET OUR TEAM
Meet our team of experts in in-vivo biomarkers for oncology with strong competencies in executive leadership, R&D, industry regulations and operations:
Bernard Landes
Chairman & CEO
Former General Manager of Cyclopharma with 25 years of experience in pharmaceutical industry and IT
Peter Webner
CEO, US
Former General Manager of Zevacor Pharma with 25 years of experience in radiopharmaceutical industry
Jean-Bernard Deloye
Head of Market Access
Former Deputy General Manager of Cyclopharma with 25 years of experience in radiopharmaceutical industry
Yann Bouvet
Head of R&D
Former Pharmaceutical and Industrial Development Director of Cyclopharma with 10 years of experience in R&D projects
Jerome Francillard
CFO
Former CFO of Energy Pool with 15 years of experience in consulting and financing growth
Together, we are dedicated to
transforming oncology >
WITH THE SUPPORT OF
